Vaccine comprising beta-herpesvirus

An attenuated in vivo beta-herpesvirus, wherein the beta-herpesvirus comprises a first heterologous nucleic acid comprising a nucleotide sequence encoding a human UL16 Binding Protein 2 (ULBP2) that replaces a viral gene encoding the protein UL16 or a homolog thereof, wherein the beta-herpesvirus encodes a second heterologous nucleic acid, wherein the second heterologous nucleic acid is a heterologous nucleic acid coding for a peptide, oligo-peptide, polypeptide or protein, wherein the peptide, oligopeptide, polypeptide or protein constitutes or comprises at least one antigen, wherein the antigen is a tumor antigen, and wherein the antigen is suitable for being recognized by a receptor of an immune cell and triggering an immune response against said antigen.